Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Nitric Oxide Nasal Spray

<< Previous

Bullboard Posts

Next >>

Comment by WORKINMONTANAon Feb 28, 2021 8:41am

267 Views

Post# 32680942

RE:RE:Nitric Oxide Nasal Spray

Jmk2454 wrote:
Can anyone tell me how long it will take to develop R-107? Trials of this nature could take as short as 30 days for results. The Claritas website says "Claritas will develop R-107 as a therapy . . . " There is certainly positive data about nitric oxide but will Claritas need to do their own clinical trials? Is there more information somewhere that I'm missing? The Kal 1816 market for pain killers is going to be a Diamond mine worth billions and billions yearly https://www.pharmaceuticalprocessingworld.com/u-s-painkiller-market-to-reach-5-9-billion-by-2023/

indaknownewfie wrote:
Claritas believes that R-107 has potential to become an effective front-line therapy for patients who contract Covid-19 infection. R-107 is anticipated to be effective against all strains because its mechanism of action is not dependent upon the specifics of the viral structure. The Company believes that R-107 may also have potential as a prophylactic to prevent COVID-19 infection, and the Company intends to also develop R-107 as a nasal spray for this purpose.

Israel is also considering defining the spray as a medical device, NOT A DRUG, she added, (Gilly Regev, CEO Sanotize) which means it could get approval in that country much quicker. Directly from the Global news coverage about the NO spray from SaNOtize.

We know that Claritas has strong Isreali ties so its not far fetched to think our spray could be commercialized quickly